AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02088970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic treatment
Description: If not the contact lens wearer -> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -> Fungus.~= Fortum + vancomycin + Fungizone
Study NCT02088970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic treatment
Description: If not the contact lens wearer -> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -> Fungus.~= Fortum + vancomycin + Fungizone
Study NCT05597475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GLP-1R PET
Description: Beta cell function (tests) and measure for beta cell mass (PET)
Study NCT03203057 — intervention group
Intervention type: OTHER
Intervention: coronary occlusion
Description: percutaneous coronary intervention
Study NCT02524821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: 3 capsules each containing 0.75 mg
Study NCT02524821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis100
Description: 3 capsules each containing 0.75 mg
Study NCT02524821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1 tablet of 850 mg
Study NCT02524821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1 tablet of 850 mg
Study NCT04699019 — intervention group
Intervention type: OTHER
Intervention: Four speeds
Description: Four speeds ranging from a set walking speed up to 9 mph
Study NCT04699019 — intervention group
Intervention type: OTHER
Intervention: Foot Strike Pattern
Description: Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
Study NCT03417908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
Study NCT03417908 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
Study NCT01991990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single i.v. infusion
Study NCT01991990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: Single 8 mg/kg i.v. infusion
Study NCT01967355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lipid apheresis
Study NCT02348892 — intervention group
Intervention type: OTHER
Intervention: Coordinator
Description: Patients in complex situation taken care by coordinator
Study NCT02348892 — intervention group
Intervention type: OTHER
Intervention: Classic plan
Description: Patients in complex situation taken care by classic plan
Study NCT00888550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Op Splinting
Description: Splint will applied post-operatively and will remain on for two weeks
Study NCT00888550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Splinting
Description: Patient will be discharged post-operatively without a splint on their lower leg.
Study NCT00942175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
Study NCT00942175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Lansoprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
Study NCT00942175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Dexlansoprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
Study NCT00942175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Omeprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
Study NCT00942175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel and Esomeprazole
Description: Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
Study NCT03581266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye/Wheat
Description: Mechanistic study of glucose kinetics after ingestion two kinds of bread
Study NCT01066585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Cream
Description: Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
Study NCT01066585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle control
Description: Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Study NCT02305095 — intervention group
Intervention type: DRUG
Intervention: FDC I/H
Description: All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
Study NCT01833611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5mg qd
Study NCT01833611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd
Study NCT04489745 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study NCT04489745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Study NCT01891500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
Study NCT01891500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen Gas
Description: Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
Study NCT01891500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crossover iNO
Description: Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
Study NCT03521375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
Study NCT03521375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Assisted Thoracoscopic Surgery (VATS)
Description: VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
Study NCT03821025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: Palliation of malignant biliary obstruction
Study NCT03104894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Glands Massage
Description: Meibomian gland expression
Study NCT03104894 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Meibomian Glands Massage
Description: Touching the eyelids gently
Study NCT03104894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meibomian Massage device
Description: Meibomian glands expression with applicator
Study NCT04126083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine Oral Tablet
Description: lofexidine 0.54 mg 4 times daily
Study NCT02873936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02873936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02873936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02873936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
Study NCT02873936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
Study NCT04374760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-intervention
Description: SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
Study NCT00805272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QTF-TB Gold and T-SPOT TB
Description: evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
Study NCT02787187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy with Standard lymphadenectomy
Description: Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Study NCT02787187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with Extended lymphadenectomy
Description: Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
Study NCT02559297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
Study NCT02559297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
Study NCT04360980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: 1.5 mg loading then 0.5 mg BID P.O
Study NCT02282150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
Study NCT02282150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Plenadren
Description: 10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
Study NCT01710995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zegerid
Study NCT01710995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losec
Study NCT00123292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
Study NCT00123292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
Study NCT00123292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
Study NCT01475175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT pacing at rest and during exercise
Description: CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
Study NCT02836028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib monotherapy 1mg/day orally
Study NCT02836028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Talazoparib monotherapy 1mg/day orally
Study NCT02836028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 37.5 mg/m2 on days 1-5 of each cycle
Study NCT04090710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab/ Nivolumab
Description: induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
Study NCT04090710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + Ipilimumab/Nivolumab
Description: SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
Study NCT02361541 — intervention group
Intervention type: PROCEDURE
Intervention: HCV screening
Description: HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
Study NCT01289236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milnacipran
Description: 1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
Study NCT01289236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
Study NCT01289236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
Study NCT04651621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation over the SMA
Description: Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
Study NCT04651621 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous theta burst stimulation over the SMA
Description: The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
Study NCT01014325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract
Description: sublingual application
Study NCT01014325 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sublingual application
Study NCT02426476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active heart rate variability biofeedback training
Description: resonant frequency breathing, attention focusing, positive emotional state
Study NCT02426476 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham HRVB training
Description: passive relaxation
Study NCT02023775 — intervention group
Intervention type: DEVICE
Intervention: Melody valve implantation
Study NCT04018794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioral/organizational skills intervention augmented with digital health application
Description: Behavioral/organizational skills intervention with digital health application augmentation
Study NCT02691208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
Study NCT02691208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
Study NCT00865397 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
Study NCT00725881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
Study NCT00725881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
Study NCT00627653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 148mg daily for 30 days
Study NCT02308982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins, Intravenous (Privigen)
Study NCT02308982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04021836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3d evaluation of nasolabial change
Description: Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
Study NCT02499861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Genistein
Description: intravenous Decitabine with oral genistein
Study NCT03127384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lidocaine
Description: Hyaluronic acid based filler
Study NCT03127384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No-treatment control
Study NCT00870402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg per day for 9 months
Study NCT00870402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet per day for nine months
Study NCT00277186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Care Continuum
Description: Patient experience surgery through newly designed arthroplasty continuum
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor granule
Description: A P2Y12 receptor inhibitor provided as granule for suspension.
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor granule
Description: A P2Y12 receptor inhibitor provided as granule for suspension.
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets
Description: A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.